Basis: Evaluating Sirtuin Supplements To Benefit Elderly Trauma Patients (BES2T BET)

Brief description of study

Adults 65 and older are more likely to have significant injuries from minor things like falls. They can have problems regaining strength due to sarcopenia (loss of muscle tissue as part of natural aging process). Nicotinamide riboside/pterstilbene (Basis) is commercially available nutraceutical. This randomized, double blind placebo controlled trial will investigate the impact of Basis on the functional recovery of elderly patients (65 years or older) admitted to the trauma service post-injury. Basis (or placebo) will be taken orally for 90 days. Bioactivity will be tracked daily. Functional, cognitive, and biochemical assays will be assessed at 24 hrs, discharge, 6 weeks, and then at 3 months post injury. See Protocol Section 4.1 for Inclusion and Exclusion Criteria

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
trauma, Recovery of Function
Age: - 99 Years
Gender: All

Updated on 09 Mar 2024. Study ID: 829947

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).